Skip to main content

Tecfidera Disease Interactions

There are 4 disease interactions with Tecfidera (dimethyl fumarate).

Major

Immunosuppressive agents (applies to Tecfidera) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

References

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories (2001):
  2. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  3. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline (2011):
  4. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  5. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  6. "Product Information. Tecfidera (dimethyl fumarate)." Biogen (2013):
  7. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  8. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):
  9. "Product Information. Gamifant (emapalumab)." Sobi Inc (2018):
  10. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
  11. "Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals (2021):
View all 11 references
Major

Immunosuppressive agents (applies to Tecfidera) PML

Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.

References

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories (2001):
  2. "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc (2004):
  3. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  4. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline (2011):
  5. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  6. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  7. "Product Information. Tecfidera (dimethyl fumarate)." Biogen (2013):
  8. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  9. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):
View all 9 references
Moderate

Dimethyl fumarate (applies to Tecfidera) liver

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of dimethyl fumarate may cause liver injury. Elevations of hepatic transaminases were observed during controlled trials. It is recommended to obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels prior to treatment and during treatment, as clinically indicated. Caution is recommended when prescribing this agent in patients at risk for liver injury. Discontinue therapy if clinically significant liver injury induced by this agent is suspected.

References

  1. "Product Information. Tecfidera (dimethyl fumarate)." Biogen (2013):
Moderate

Dimethyl fumarate (applies to Tecfidera) lymphopenia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Lymphocytopenia

The use of dimethyl fumarate may decrease lymphocyte counts. It is recommended to obtain a CBC count before initiating treatment, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interrupting therapy in patients with lymphocyte counts less than 0.5 x 109/L persisting for more than six months and withhold treatment from patients with serious infections until resolution. Caution is recommended and the decisions about whether or not to restart therapy in these patients should be individualized based on clinical circumstances.

References

  1. "Product Information. Tecfidera (dimethyl fumarate)." Biogen (2013):

Tecfidera drug interactions

There are 354 drug interactions with Tecfidera (dimethyl fumarate).

Tecfidera alcohol/food interactions

There is 1 alcohol/food interaction with Tecfidera (dimethyl fumarate).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.